Fig. 6.

Effect of TKSE on tumor growth in the CT-26 tumor-bearing mouse model. CT-26 cells (1 × 10⁶) were subcutaneously inoculated into the right flanks of BALB/c mice. When tumor volumes reached ~ 50 mm³, TKSE (100 or 300 mg/kg) was orally administered five times per week for 3 weeks and 5-Fu (50 mg/kg) was intraperitoneally administered twice per week for 3 weeks. Body weights and tumor sizes were recorded twice and three times per week, respectively. a Tumor growth curve of mice treated with vehicle (Con), 100 mg/kg TKSE (TK-L), 300 mg/kg TKSE (TK-H), or 50 mg/kg 5-Fu (5-Fu) during treatment. b Tumor weights. c Body weight changes of mice in each experimental group. d Serum levels of the liver-specific enzymes GOT and GPT. N; normal group, T; tumor groups. NS not significant. Results are presented as means ± SEMs (n = 5). Significance vs. the vehicle-treated tumor-bearing controls, *p < 0.05, ***p < 0.001